The objective of the study was to investigate the effectiveness and efficacy of the randomized, parallel, and controlled trial of
Traditional Chinese Medicine, general
acteoside of Rehmanniae leaves, compared with
piperazine ferulate in the treatment of primary chronic
glomerulonephritis. Rehmanniae leaves and
piperazine ferulate can reduce
proteinuria and erythrocyturia effectively in the treatment of primary chronic
glomerulonephritis. A total of 400 patients diagnosed with primary chronic
glomerulonephritis were recruited from outpatient clinics and were randomly assigned to the treatment group (general
acteoside of Rehmanniae leaves, two 200mg
tablets, bid) or the control group (
piperazine ferulate, four 50-mg
tablets, bid ). The primary outcome was 24-h urinary
protein. Secondary outcome measures included estimated glomerular filtration rate (eGFR), erythrocyturia, and
electrolytes. After 8 weeks of treatment, the treatment group and the control group showed a mean reduction in 24-h
proteinuria of 34.81% and 37.66%. The 95% CI of difference of the mean reduction in 24-h
proteinuria between the two groups was [-11.50%, 5.80%]. No significant differences were found between the two groups in the erythrocyturia reduction. Neither group showed obvious changes between baseline and 8 weeks in eGFR or
electrolytes. Adverse events occurred at a similarly low rate in the treatment group (1.5%) and control group (2.5%, P = 0.7238). Both general
acteoside of Rehmanniae leaves and
piperazine ferulate can reduce
proteinuria and erythrocyturia effectively in the treatment of primary chronic
glomerulonephritis.